KOREA WHO
-
-
CEO of LigaChem Biosciences
Kim Yong-zu
Pioneer in Antibody-Drug Conjugates (ADC), Advances Drug Development Under Orion Group
-
Last Updated on Jan 8, 2025
-
CEO of LigaChem Biosciences
Copy Url : https://www.koreawho.com/profile/KimYongzu- Life Summary
Kim Yong-zu is the CEO of LigaChem Biosciences.
He was born on May 17, 1956, in Daejeon.
He graduated from Daejeon High School and the Department of Chemistry at Seoul National University. He earned a master’s degree and a doctorate in organic chemistry from the Korea Advanced Institute of Science and Technology (KAIST).
After serving as the director of the LG Chem Technology Research Institute, he worked as the head of the U.S. branch of LG Life Sciences and as the director of the New Drug Research Institute at the Technology Research Institute.
In 2006, he founded LegoChem Biosciences (now LigaChem Biosciences), which focuses on pharmaceutical research and development.
He transferred the position of the largest shareholder to Orion Group and is currently leading the company as the second-largest shareholder.
He has focused on the field of Antibody-Drug Conjugates (ADC), a targeted cancer therapy, and aims to establish the company as a new drug development enterprise that conducts its own clinical trials.
#KimYongzu #LigaChemBiosciences #biotechnology #pharmaceuticals #organicchemistry #newdrugdevelopment #antibodydrugconjugates #cancertherapy #OrionGroup #biopharma
He was born on May 17, 1956, in Daejeon.
He graduated from Daejeon High School and the Department of Chemistry at Seoul National University. He earned a master’s degree and a doctorate in organic chemistry from the Korea Advanced Institute of Science and Technology (KAIST).
After serving as the director of the LG Chem Technology Research Institute, he worked as the head of the U.S. branch of LG Life Sciences and as the director of the New Drug Research Institute at the Technology Research Institute.
In 2006, he founded LegoChem Biosciences (now LigaChem Biosciences), which focuses on pharmaceutical research and development.
He transferred the position of the largest shareholder to Orion Group and is currently leading the company as the second-largest shareholder.
He has focused on the field of Antibody-Drug Conjugates (ADC), a targeted cancer therapy, and aims to establish the company as a new drug development enterprise that conducts its own clinical trials.
#KimYongzu #LigaChemBiosciences #biotechnology #pharmaceuticals #organicchemistry #newdrugdevelopment #antibodydrugconjugates #cancertherapy #OrionGroup #biopharma
- Life Summary
- Career Highlights & Challenges
- · LigaChem Biosciences Governance Structure
- · Increase in ADC Licensing Revenue Improves 2024 Performance
- · Completion of Patient Enrollment for Phase 1b Trial of ROR1 ADC
- · LNCB74 Phase 1 Approved in the US
- · Preclinical Data of Next-Generation Immuno-Oncology Candidate LCB39 Announced
- · Rodrigo Ruiz Soto, Former ImmunoGen Executive, Joins as CMO
- · Two ADC Technology Licensing Agreements Signed with Japan's Ono Pharmaceutical
- · LCB14 Shows Potential as Substitute for ENHERTU in Phase 2 Gastric Cancer Trial
- · Majority Stake Transferred to Orion Group
- · Renamed to LigaChem Biosciences
- · Technology Licensing Agreement Signed with Janssen for LCB84
- · HER2 ADC Phase 1 Dosing Begins
- · New Antibody Technology Licensing Agreement with Switzerland's Elthera
- · Multi-Target ADC Collaboration and Licensing Agreement with Amgen
- · ADC Technology Licensing Agreement with SOTIO Biotech
- · Collaboration and Licensing Agreement with Antengene Biologics in China
- · Headquarters Relocated to New Building
- · History of LigaChem Biosciences
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Awards & Recognitions
- Additional Information
- Notable Quotations
- Infographic & Photos